



NORGINE'S MANUFACTURING SITE IN HENGOED, WALES CELEBRATES EXPORTING MOVIPREP® TO THE USA

Norgine's manufacturing site at Hengoed celebrated a major achievement last week - the export of MOVIPREP® to the USA. MOVIPREP® is indicated for bowel cleansing prior to colonoscopy.

Norgine, the European specialty pharmaceutical company, announced in August 2006 that the US Food and Drug Administration (FDA) had granted marketing approval for MOVIPREP®. Norgine granted exclusive marketing rights for MOVIPREP® in the USA to Salix Pharmaceuticals in December 2005.

Ben Davies, Norgine's Site Director was joined in the celebrations by First Minister the Rt Hon Rhodri Morgan, Jeff Cuthbert AM, Member for Caerphilly, Cllr Elizabeth Aldworth, Mayor of Caerphilly and other leading dignitaries and health professionals to mark this important event for Norgine.

Commenting on the event, the Rt Hon Rhodri Morgan said; "It's a pleasure to be able to join Norgine to celebrate the successful launch of MOVIPREP® on the US market. I am pleased to see a company that continues to provide high quality, well-paid jobs to Wales succeeding in the global market. I commend Norgine as an example to other companies – you too can succeed in the global economy."

Peter Stein, Norgine's Chief Executive Officer said; "This is Norgine's first product approval in the USA, and it's a significant milestone for our company. It is also a huge achievement for the Hengoed Team and we're very proud of them. We have every confidence that MOVIPREP® can achieve great success both in the USA and Europe".

ENDS

Notes to editor

Colorectal cancer screening

Colonoscopy is very effective in the early detection of colorectal cancer, and about 90% of colorectal cancers and deaths are preventable if detected early. The American Cancer Society estimates that more than 30,000 lives could be saved annually by widespread screening.

The majority of colonoscopies performed in the US are indicated for colorectal cancer screening, and more than 10 million uses of bowel cleansing agents were prescribed during 2005. The use of a bowel cleansing agent is a pre-requisite to a colonoscopy.

Norgine

Norgine is an independent, successful European specialty pharmaceutical company that has been established for 100 years and has a presence in all the major European markets. In 2006 Norgine's sales were €193 million, the 20th consecutive year of double-digit growth. The company employs 1,000 people, of whom 350 are in sales and marketing.

Norgine's current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. MOVICOL[®] for the treatment of chronic constipation and faecal impaction and ORAMORPH[®] for the treatment of moderate to severe pain associated with cancer. Norgine recently launched MOVIPREP[®] indicated for bowel cleansing prior to colonoscopy.

Norgine has an active Research and Development effort and currently has products at various stages of clinical development. Norgine has two manufacturing sites; Hengod in the UK and also in Dreux, France.

Norgine's website is www.norgine.com

For further information, please contact:

Paul Pay, Vice-President Global Marketing and Business Development,
Norgine

T: +44 (0)1895 453710

E: ppay@norgine.com

Louise Blakeborough, Chapter Five

T: +44 (0)1306 731800

E: lblakeborough@chapterfive.co.uk